Sign Up to like & get
recommendations!
2
Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.929223
Abstract: Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone,…
read more here.
Keywords:
research based;
bibliometric research;
frontier trends;
hotspots frontier ... See more keywords